Current Pharmaceutical Design
Title: Editorial [ Therapeutics for Protein Misfolding Diseases Executive Editor: Claudio Soto ]
Volume: 12 Issue: 20
Author(s): Claudio Soto
Affiliation:
Export Options
About this article
Cite this article as:
Soto Claudio, Editorial [ Therapeutics for Protein Misfolding Diseases Executive Editor: Claudio Soto ], Current Pharmaceutical Design 2006; 12 (20) . https://dx.doi.org/10.2174/138161206777698864
DOI https://dx.doi.org/10.2174/138161206777698864 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
12
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In the Rush for Green Gold: Can Green Tea Delay Age-Progressive Brain Neurodegeneration?
Recent Patents on CNS Drug Discovery (Discontinued) Drugs of Abuse in Pregnancy, Poor Neonatal Development, and Future Neurodegeneration. Is Oxidative Stress the Culprit?
Current Pharmaceutical Design New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Understanding the Role of Hypoxia Inducible Factor During Neurodegeneration for New Therapeutics Opportunities
Current Neuropharmacology Commentary: Neurorestoratology: A Concept and Emerging Discipline in the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Up-Regulation of Hypoxia-Inducible Factor (HIF)-1α and HIF-Target Genes in Cortical Neurons by the Novel Multifunctional Iron Chelator Anti-Alzheimer Drug, M30
Current Alzheimer Research siRNA Therapy, Challenges and Underlying Perspectives of Dendrimer as Delivery Vector
Current Pharmaceutical Design Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Role of Nitric Oxide Signaling Pathways in Brain Injuries
Current Chemical Biology Cannabinoid Modulation of Neuroinflammatory Disorders
Current Neuropharmacology Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia
Current Neurovascular Research RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research Glitazones, PPAR-γ and Neuroprotection
Mini-Reviews in Medicinal Chemistry Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease
Current Genomics Editorial [Pharmacology and Therapeutic Activity of Purinergic Drugs for Disorders of the Nervous System]
CNS & Neurological Disorders - Drug Targets Aluminum Induced Immunoexcitotoxicity in Neurodevelopmental and Neurodegenerative Disorders
Current Inorganic Chemistry (Discontinued) Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
CNS & Neurological Disorders - Drug Targets